MedTrace Logo

A Study in Healthy Subjects to Investigate Pharmacokinetics of AZD5423 When Administered in Different Ways

NCT01635985 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2015-01-14

No results posted yet for this study

Summary

The purpose of this study is to look at drug levels of AZD5423 in blood when the drug is administered in different ways - orally, intravenously or inhaled (with four different devices), to healthy subjects

Conditions

  • Bioavailability and AUC

Interventions

DRUG

AZD5423

solution for injection, administered as intravenous infusion Corr to total dose of 250 µg AZD5423

DRUG

AZD5423

nebuliser suspension, inhaled via Spira, corr to approximately 300 µg lung deposited dose AZD5423

DRUG

AZD5423

nebuliser suspension, inhaled via I-neb, corr to approximately 300 µg lung deposited dose AZD5423

DRUG

AZD5423

nebuliser suspension to be administered orally, corr to a total dose of 1200 µg AZD5423

DRUG

AZD5423

dry powder inhaled via Turbuhaler, corr to approximately 200 µg lung deposited dose AZD5423

DRUG

AZD5423

dry powder inhaled via New Dry Powder Inhaler, corr to approximately 200 µg lung deposited dose AZD5423

Sponsors & Collaborators

Principal Investigators

  • Carin Jorup, MD · AstraZeneca R&D, Molndal Sweden

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01635985 on ClinicalTrials.gov